Maker of much-debated ALS drug says it may stop selling it after study showed it didn’t work
WASHINGTON — The maker of a much-debated drug for Lou Gehrig’s disease said Friday its therapy failed to help patients in a large follow-up study, but stopped short of committing to follow through on a prior pledge to pull the drug from the U.S. market. The Food and Drug Administration approved Amylyx Pharmaceuticals’ Relyvrio in … Read more
